simvastatin has been researched along with Cavernitis, Fibrous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cellek, S; Ilg, MM; Ralph, DJ | 1 |
| Albersen, M; De Ridder, D; Ilg, MM; Milenkovic, U; Ramazani, Y; Zuccato, C | 1 |
2 other study(ies) available for simvastatin and Cavernitis, Fibrous
| Article | Year |
|---|---|
Statins synergize with phosphodiesterase type 5 inhibitors but not with selective estrogen receptor modulators to prevent myofibroblast transformation in an in vitro model of Peyronie's disease.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myofibroblasts; Penile Induration; Phosphodiesterase 5 Inhibitors; Selective Estrogen Receptor Modulators; Simvastatin; Tamoxifen; Transforming Growth Factor beta1; Vardenafil Dihydrochloride | 2023 |
Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie's disease-derived fibroblasts via inhibition of YAP/TAZ nuclear translocation.
Topics: Amides; Anticholesteremic Agents; Cells, Cultured; Humans; Intracellular Signaling Peptides and Proteins; Male; Myofibroblasts; Penile Induration; Pyridines; Real-Time Polymerase Chain Reaction; rho-Associated Kinases; Simvastatin | 2019 |